`BIB_335`

Lovat P, Roesch A et al. (Newcastle University + AmLo Biosciences). AMBLor — autophagy-based immunohistochemistry prognostic biomarker for Stage IB/IIA cutaneous melanoma. Originating papers Br J Cancer 2017; Cancers 2023; commercial-stage 2024-2025. The only Tier 1 university group with a deliverable specifically aimed at Stage IB/IIA risk-stratification. Watch for SMC/NICE evaluation of AMBLor over 2026-2027; not currently NHS-commissioned. Patient-specifically-relevant: would re-stratify residual recurrence risk at IB with primary-biopsy IHC. [Tasks: 06, 15, 17, 19b] Tier: 3 (single-institu…

Evidence grade: C
Tier: 3 (sin
Cited by tasks: 06, 15, 17, 19b
Identifiers: —

Full extracted findings & patient-implication analysis: bibliography/BIB_335/findings.md (research corpus). This page is a short context summary — not individualised medical advice.